ALS Ltd

ALQ: XASX (AUS)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|.WFLOCK|@m&y$LOCK|W@>w$H

ALS Earnings: Commodities Momentum Offsets Mixed Life Sciences Results

Materials testing specialist ALS reported a 24% increase in underlying fiscal 2026 NPAT to AUD 363 million. Revenue rose 11% to AUD 3.3 billion while the underlying EBITDA margin lifted by 9 basis points to 22.1%. The final dividend increased 17% to AUD 23.1 cents, franked to 30%.

Sponsor Center